ARA-290 (Innate Repair Receptor Agonist)

ARA-290 is an 11-amino acid peptide corresponding to a helical surface loop of erythropoietin that has been identified as the tissue-protective domain of the EPO molecule. Preclinical research has investigated this compound's ability to activate the innate repair receptor — a heterodimeric complex distinct from the classical EPO receptor — without stimulating erythropoiesis or haematopoietic pathways. This receptor selectivity has made ARA-290 a research tool for studying EPO's tissue-protective functions independent of its blood cell-producing effects.

In preclinical neuropathy research, ARA-290 has been studied in animal models of diabetic peripheral neuropathy and small fibre neuropathy. Laboratory investigations have examined its effects on sensory nerve function, intraepidermal nerve fibre density, and inflammatory markers in relevant rodent models. These studies have characterised how innate repair receptor activation may influence peripheral nerve biology and inflammation in neuropathy model systems.

The compound has also been studied in preclinical models of metabolic disease, including diabetes and metabolic syndrome. Animal model investigations have examined ARA-290's effects on pancreatic beta cell biology, insulin secretion, and systemic inflammatory marker profiles. These preclinical metabolic studies have explored whether innate repair receptor signalling influences the metabolic consequences of inflammatory tissue damage in relevant laboratory model systems.